Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff; Novo searching for new CEO with Sørensen out as soon as next year;

> Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff. Editor's Corner

> Novo searching for new CEO with Sørensen out as soon as next year. More

> Roche builds CLL case for Gazyva in two-horse race with GSK. Article

> Actavis goes 1-for-2 with FDA as regulators knock blood pressure combo. Story

> Sen. Warren urges CMS to get on board, encourage UDI info in insurance claims forms. News

Suggested Articles

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.